US FDA Panel For Sarepta’s Gene Therapy Heavy On Temporary Voting Members

Telephone
In setting the panel for the Sarepta gene therapy meeting, the US FDA has called on experts from prior muscular dystrophy drug reviews. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers